Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis

Código QR

Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis

Abstract We conducted a systematic review and meta-analysis investigating the association between overweight and outcome in triple-negative breast cancer (TNBC) patients. We searched PubMed and Embase using variations of the search terms triple-negative breast cancer (population), overweight and/or...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sixten Harborg, Robert Zachariae, Julia Olsen, Maja Johannsen, Deirdre Cronin-Fenton, Henrik Bøggild, Signe Borgquist
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3ec193fe350642578857f5c1bda1b19c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis
por: Gábor Cserni, et al.
Publicado: (2021)

Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer
por: Anna E. M. Bastiaansen, et al.
Publicado: (2020)

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells
por: Swanner J, et al.
Publicado: (2015)

Assessing Clinicopathological Features and Prognosis of Triple-Negative Breast Cancer Patients: A Single-Center Study in Turkey
por: Saliha Karagöz Eren, et al.
Publicado: (2021)

A triple negative breast cancer: what it is not!
por: Katakkar SB
Publicado: (2012)

Triple negative breast cancer: an Indian perspective
por: Akhtar M, et al.
Publicado: (2015)

Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.
por: Wen-Hung Kuo, et al.
Publicado: (2012)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zilin Zhang, et al.
Publicado: (2021)

High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
por: Maria Inasu, et al.
Publicado: (2021)

BRCA2 mutations and triple-negative breast cancer.
por: Peter Meyer, et al.
Publicado: (2012)

Triple-negative breast cancer: treatment challenges and solutions
por: Collignon J, et al.
Publicado: (2016)

Opportunities for metastatic triple negative breast cancer therapy
por: Inna P. Ganshina, et al.
Publicado: (2021)

Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021)

MicroRNA-223 is Associated with Resistance Towards Platinum-based Chemotherapy and Worse Prognosis in Indonesian Triple-negative Breast Cancer Patients
por: Purwanto I, et al.
Publicado: (2021)

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
por: Corey Speers, et al.
Publicado: (2017)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
por: Marina K. Ibragimova, et al.
Publicado: (2021)

Molecular heterogeneity in adjacent cells in triple-negative breast cancer
por: Huebschman ML, et al.
Publicado: (2015)

Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
por: Paolo Peterlongo, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response
por: Zeng-Jie Weng MM, et al.
Publicado: (2021)

Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
por: L. E. Anselmino, et al.
Publicado: (2021)

A new immunochemical strategy for triple-negative breast cancer therapy
por: Chih-Wei Lin, et al.
Publicado: (2021)

Peptide density targets and impedes triple negative breast cancer metastasis
por: Daxing Liu, et al.
Publicado: (2018)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher B, et al.
Publicado: (2016)

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
por: Inna P. Ganshina, et al.
Publicado: (2021)

Non-Coding RNAs Associated With Radioresistance in Triple-Negative Breast Cancer
por: Alberto Aranza-Martínez, et al.
Publicado: (2021)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
por: Yuanfang Xin, et al.
Publicado: (2021)

Kinetic information from dynamic contrast-enhanced MRI enables prediction of residual cancer burden and prognosis in triple-negative breast cancer: a retrospective study
por: Ayane Yamaguchi, et al.
Publicado: (2021)

Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.
por: Katsuhiro Yoshikawa, et al.
Publicado: (2021)

Expression of LGR5 in mammary myoepithelial cells and in triple-negative breast cancers
por: Hyun Ju Lee, et al.
Publicado: (2021)

Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
por: Vanessa Y. C. Sung, et al.
Publicado: (2021)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva JL, et al.
Publicado: (2021)

Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment
por: Bowen Gao, et al.
Publicado: (2021)

Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling
por: Radhakrishnan Vishnubalaji, et al.
Publicado: (2021)

Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling
por: Hao Huang, et al.
Publicado: (2021)

Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer
por: Alessandro De Vita, et al.
Publicado: (2021)

A DNA methylation-based liquid biopsy for triple-negative breast cancer
por: Katrina Cristall, et al.
Publicado: (2021)

Filamin-A expression in triple-negative breast cancer and its clinical significance
por: Abderrahman Ouban
Publicado: (2021)

RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis
por: Zhuming Yin, et al.
Publicado: (2021)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
por: Ye J, et al.
Publicado: (2016)

Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer
por: Wenjie Zhao, et al.
Publicado: (2021)